Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W N Deininger

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Blood|May 15, 2007
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W N Deininger
Nature Reviews. Cancer|June 24, 2017
Turning the tide in myelodysplastic/myeloproliferative neoplasmsMichael W N Deininger, Jeffrey W Tyner, Eric Solary
Cell Cycle (Georgetown, Tex.)|December 2, 2005
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?Thoralf Lange, Byung Park, Stephanie G Willis, et al.
Cancer Cell|February 16, 2005
AMN107: tightening the grip of imatinibThomas O'Hare, Denise K Walters, Michael W N Deininger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Practical management of patients with chronic myeloid leukemia receiving imatinibMichael W N Deininger, Stephen G O'Brien, John M Ford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2010
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemiaThomas O'Hare, Michael W N Deininger, Christopher A Eide, et al.
The Journal of Molecular Diagnostics : JMD|February 16, 2008
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapyJennifer Laudadio, Michael W N Deininger, Michael J Mauro, et al.
Blood|July 24, 2009
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinibRichard D Press, Stephanie G Willis, Jennifer Laudadio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinibThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic responseRichard D Press, Chad Galderisi, Rui Yang, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Blood|May 15, 2007
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W N Deininger
Nature Reviews. Cancer|June 24, 2017
Turning the tide in myelodysplastic/myeloproliferative neoplasmsMichael W N Deininger, Jeffrey W Tyner, Eric Solary
Cell Cycle (Georgetown, Tex.)|December 2, 2005
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?Thoralf Lange, Byung Park, Stephanie G Willis, et al.
Cancer Cell|February 16, 2005
AMN107: tightening the grip of imatinibThomas O'Hare, Denise K Walters, Michael W N Deininger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Practical management of patients with chronic myeloid leukemia receiving imatinibMichael W N Deininger, Stephen G O'Brien, John M Ford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2010
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemiaThomas O'Hare, Michael W N Deininger, Christopher A Eide, et al.
The Journal of Molecular Diagnostics : JMD|February 16, 2008
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapyJennifer Laudadio, Michael W N Deininger, Michael J Mauro, et al.
Blood|July 24, 2009
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinibRichard D Press, Stephanie G Willis, Jennifer Laudadio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinibThomas O'Hare, Denise K Walters, Eric P Stoffregen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic responseRichard D Press, Chad Galderisi, Rui Yang, et al.
Pageof 6